Douglas B. Johnson

Statistics

Publications

Citations

1.9K

H-Index

Active since

2018

Affiliations

Vanderbilt University Medical Center(Current)

Inserm

Assistance Publique – Hôpitaux de Paris

Sorbonne Université

Pitié-Salpêtrière Hospital

Douglas B. Johnson is an author at Vanderbilt University Medical Center specializing in immune checkpoints, immune checkpoint inhibitors, and checkpoint inhibitor therapy.

Publications per year

2018–2025

Publications

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Joe‐Elie Salem, Ali Manouchehri, Melissa Moey et al. · The Lancet Oncology · 2018 · 1.2K citations

Life Sciences, Immunology, Pharmacology +16

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Spencer C. Wei, Wouter C. Meijers, Margaret L. Axelrod et al. · Cancer Discovery · 2020 · 272 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S. Kim et al. · npj Breast Cancer · 2020 · 206 citations · Full text

Medicine, Oncology, Pathology +16

Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis

Virginie Grouthier, Bénédicte Lebrun‐Vignes, Melissa Moey et al. · The Oncologist · 2020 · 124 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update

Kylie Fletcher, Douglas B. Johnson · Journal for ImmunoTherapy of Cancer · 2024 · 64 citations · Full text

Life Sciences, Immunology, Oncology +12

1–5 of 6